Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma

Journal of Urology

Volumn 159, Issue 6, 1998, Pages 2023-2029

  Conrad, Stefan ^a   Graefen, Markus ^a   Pichlmeier, Uwe ^a   Henke, Rolf Peter ^a   Hammerer, Peter G ^a   Huland, Hartwig ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Biopsy; Lymph node excision; Neoplasm metastasis; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; HIGH RISK POPULATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPHADENECTOMY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CARCINOMA;

EID: 0032412561     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63234-8     Document Type: Article

References (48)

1. Wolf, J. S., Jr., Cher, M., Dall'era, M., Presti, J. C., Jr., Hricak, H. and Carroll, P. R.: The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J. Urol., 153: 993, 1995.
2. Hammerer, P., Huland, H. and Sparenberg, A.: Digital rectal examination, imaging and systematic-sextant biopsy in identifying operable lymph node-negative prostatic carcinoma. Eur. Urol., 22: 281, 1992.
3. Mukamel, E., Hannah, J., Barbaric, Z. and deKernion, J. B.: The value of computerized tomography scan and magnetic resonance imaging in staging prostatic carcinoma: comparison with the clinical and histological staging. J. Urol., 136: 1231, 1986.
4. Frazier, H. A., Robertson, J. E. and Paulson, D. F.: Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival? World J. Urol., 12: 308, 1994.
5. Cheng, C. W., Bergstralh, E. J. and Zincke, H.: Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer, 71: 996, 1993.
6. Hanks, G. E., Krall, J. M., Pilepich, M. V., Asbell, S. O., Perez, C. A., Rubin, P., Sause, W. T. and Doggett, R. L.: Comparison of pathologic and clinical evaluation of lymph nodes in prostate cancer: implications of RTOG data for patient management and trial design and stratification. Int. J. Rad. Oncol. Biol. Phys., 23: 293, 1992.
7. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. N. Amer., 20: 713, 1993.
8. Gervasi, L. A., Mata, J., Easley, J. D., Wilbanks, J. H., Seale-Hawkins, C., Carlton, C. E. and Scardino, P. T.: Prognostic significance of lymph node metastases in prostate cancer. J. Urol., 142: 332, 1989.
9. McDowell, G. C., Johnson, J. W., Tenney, D. M. and Johnson, D. E.: Pelvic lymphadenectomy for staging clinically localized prostate cancer. Indications, complications, and results in 217 cases. Urology, 35: 476, 1990.
10. Donohue, R. E., Mani, J. H., Whitesel, J. A., Augspurger, R. R., Williams, G. and Fauver, H. E.: Intraoperative and early complications of staging pelvic lymph node dissection in prostatic adenocarcinoma. Urology, 35: 223, 1990.
11. Kavoussi, L. R., Sosa, E., Chandhoke, P., Chodak, G., Clayman, R. V., Hadley, H. R., Loughlin, K. R., Ruckle, H. C., Rukstalis, D., Schuessler, W., Segura, J., Vancaillie, T. and Winfield, H. N.: Complications of laparoscopic pelvic lymph node dissection. J. Urol., 149: 322, 1993.
12. Petros, J. A. and Catalona, W. J.: Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J. Urol., 147: 1574, 1992.
13. Danella, J. F., deKernion, J. B., Smith, R. B. and Steckel, J.: The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection. J. Urol., 149: 1488, 1993.
14. Campbell, S. C., Klein, E. A., Levin, H. S. and Piedmonte, M. R.: Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology, 46: 352, 1995.
15. Parra, R. O., Isorna, S., Perez, M. G., Cummings, J. M. and Boullier, J. A.: Radical perineal prostatectomy without pelvic lymphadenectomy: selection criteria and early results. J. Urol., 155: 612, 1996.
16. Stamey, T. A., Kabalin, J. N., McNeal, J. E., Johnstone, I. M., Freiha, F., Redwine, E. A. and Yang, N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J. Urol., 141: 1076, 1989.
17. Partin, A. W., Carter, H. B., Chan, D. W., Epstein, J. I., Oesterling, J. E., Rock, R. C., Weber, J. P. and Walsh, P. C.: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol., 143: 747, 1990.
18. Oesterling, J. E., Chan, D. W., Epstein, J. I., Kimball, A. W., Bruzek, D. J., Rock, R. C., Brendler, C. B. and Walsh, P. C.: Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol., 139: 766, 1988.
19. Zincke, H., Farrow, G. M., Myers, R. P., Benson, R. C., Jr., Furlow, W. L. and Utz, D. C.: Relationship between grade and stage of adenocarcinoma of the prostate and regional lymph node metastases. J. Urol., 128: 498, 1982.
20. Kramer, S. A., Spahr, J., Brendler, C. B., Glenn, J. F. and Paulson, D. F.: Experience with Gleason's histopathologic grading in prostatic cancer. J. Urol., 124: 223, 1980.
21. Sagalowsky, A. I., Milam, H., Reveley, L. R. and Silva, F. G.: Prediction of lymphatic metastases by Gleason histologic grading in prostatic cancer. J. Urol., 128: 951, 1982.
22. McNeal, J. E., Villers, A. A., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Histologic differentiation, cancer volume, and pelvic lymph node metastases in adenocarcinoma of the prostate. Cancer, 66: 1225, 1990.
23. Greskovich, F. J., Johnson, D. E., Tenney, D. M. and Stephenson, R. A.: Prostate specific antigen in patients with clinical stage C prostate cancer: relation to lymph node status and grade. J. Urol., 145: 798, 1991.
24. Roach, M.: You say either, I say either, but let's not call the whole thing off: models for predicting the risk of lymph node involvement in patients with prostate cancer. Int. J. Rad. Oncol. Biol. Phys., 34: 749, 1996.
25. Spevack, L., Killion, L. T., West, J. C. J., Rooker, G. M., Brewer, E. A. and Cuddy, P. G.: Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: an analysis of four statistical models. Int. J. Rad. Oncol. Biol. Phys., 34: 543, 1996.
26. Sullivan, L. D. and Rabbani, F.: Should we reconsider the indications for ileo-obturator node dissection with localized prostate cancer? Brit. J. Urol., 75: 33, 1995.
27. Narayan, P., Gajendran, V., Taylor, S. P., Tewari, A., Presti, J. C., Jr., Leidich, R., Lo, R., Palmer, K., Shinohara, K. and Spaulding, J. T.: The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology, 46: 205, 1995.
28. Bishoff, J. T., Reyes, A., Thompson, I. M., Harris, M. J., St Clair, S. R., Gomella, L. and Butzin, C. A.: Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology, 45: 270, 1995.
29. Berner, A., Waere, H., Nesland, J. M., Paus, E., Danielsen, H. E. and Fossa, S. D.: DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma. Brit. J. Urol., 75: 26, 1995.
30. Stone, N. N., Stock, R. G. and Unger, P.: Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. J. Urol., 154: 1392, 1995.
31. Narayan, P., Fournier, G., Gajendran, V., Leidich, R., Lo, R., Wolf, J. S., Jr., Jacob, G., Nicolaisen, G., Palmer, K. and Freiha, F.: Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology, 44: 519, 1994.
32. Bluestein, D. L., Bostwick, D. G., Bergstralh, E. J. and Oesterling, J. E.: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J. Urol., 151: 1315, 1994.
33. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I. and Walsh, P. C.: The use of prostatic specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110, 1997.
34. Kleer, E., Larson-Keller, J. J., Zincke, H. and Oesterling, J. E.: Ability of preoperative serum prostate-specific antigen value to predict pathological stage and DNA ploidy. Influence of clinical stage and tumor grade. Urology, 41: 207, 1993.
35. Ackerman, D. A., Barry, J. M., Wicklund, R. A., Olson, N. and Lowe, B.: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J. Urol., 150: 1845, 1993.
36. Stamey, T. A.: Making the most out of six systematic biopsies. Urology, 45: 2, 1995.
37. Terris, M. K., Haney, D. J., Johnstone, I. M., McNeal, J. E. and Stamey, T. A.: Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology, 45: 75, 1995.
38. Dietrick, D. D., McNeal, J. E. and Stamey, T. A.: Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. Urology, 45: 987, 1995.
39. Gleason, D. F. and Veterans Administration Cooperative Urological Research Group: Histologic grading and clinical staging of prostate carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea & Febiger, pp. 171-197, 1977.
40. Laussen, B., Sauerbrei, W. and Schumacher, M.: Classification and regression trees used for the exploration of prognostic factors measured in different scales. In: Computational Statistics. Edited by P. Dirschedl and R. Ostermann. Heidelberg: Physica, pp. 483-496, 1994.
41. Laussen, B. and Schumacher, M.: Maximally selected rank statistics. Biometrics, 48: 73, 1992.
42. deKernion, J. B., Neuwirth, H., Stein, A., Dorey, F., Stenzl, A., Hannah, J. and Blyth, B.: Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J. Urol., 144: 700, 1990.
43. Davis, G. L.: Sensitivity of frozen section examination of pelvic lymph nodes for metastatic prostate carcinoma. Cancer, 76: 661, 1995.
44. Epstein, J. I., Oesterling, J. E., Eggleston, J. C. and Walsh, P. C.: Frozen section detection of lymph node metastases in prostatic carcinoma: accuracy in grossly uninvolved pelvic lymph nodes. J. Urol., 136: 1234, 1986.
45. Schuessler, W. W., Pharand, D. and Vancaillie, T. G.: Laparoscopic standard pelvic node dissection for carcinoma of the prostate: is it accurate? J. Urol., 150: 898, 1993.
46. Troxel, S. and Winfield, H. N.: Comparative financial analysis of laparoscopic versus open pelvic lymph node dissection for men with cancer of the prostate. J. Urol., 151: 615, 1994.
47. Fournier, G. R., Jr. and Narayan, P.: Re-evaluation of the need for pelvic lymphadenectomy in low grade prostate cancer. Brit. J. Urol., 72: 484, 1993.
48. Huland, H., Hammerer, P., Henke, R. P. and Huland, E.: Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal examination, prostate specific antigen and the results of 6 systematic biopsies. J. Urol., 155: 1344, 1996.